Spoerl, S.; Gerken, M.; Schimnitz, S.; Taxis, J.; Fischer, R.; Lindner, S.R.; Ettl, T.; Ludwig, N.; Spoerl, S.; Reichert, T.E.;
et al. Prognostic Relevance of Type 2 Diabetes and Metformin Treatment in Head and Neck Melanoma: Results from a Population-Based Cohort Study. Curr. Oncol. 2022, 29, 9660-9670.
https://doi.org/10.3390/curroncol29120758
AMA Style
Spoerl S, Gerken M, Schimnitz S, Taxis J, Fischer R, Lindner SR, Ettl T, Ludwig N, Spoerl S, Reichert TE,
et al. Prognostic Relevance of Type 2 Diabetes and Metformin Treatment in Head and Neck Melanoma: Results from a Population-Based Cohort Study. Current Oncology. 2022; 29(12):9660-9670.
https://doi.org/10.3390/curroncol29120758
Chicago/Turabian Style
Spoerl, Steffen, Michael Gerken, Susanne Schimnitz, Juergen Taxis, René Fischer, Sophia R. Lindner, Tobias Ettl, Nils Ludwig, Silvia Spoerl, Torsten E. Reichert,
and et al. 2022. "Prognostic Relevance of Type 2 Diabetes and Metformin Treatment in Head and Neck Melanoma: Results from a Population-Based Cohort Study" Current Oncology 29, no. 12: 9660-9670.
https://doi.org/10.3390/curroncol29120758
APA Style
Spoerl, S., Gerken, M., Schimnitz, S., Taxis, J., Fischer, R., Lindner, S. R., Ettl, T., Ludwig, N., Spoerl, S., Reichert, T. E., & Spanier, G.
(2022). Prognostic Relevance of Type 2 Diabetes and Metformin Treatment in Head and Neck Melanoma: Results from a Population-Based Cohort Study. Current Oncology, 29(12), 9660-9670.
https://doi.org/10.3390/curroncol29120758
